Novartis AG Total Assets 2010-2022 | NVS

Novartis AG total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Novartis AG total assets for the quarter ending March 31, 2022 were $125.218B, a 2.85% increase year-over-year.
  • Novartis AG total assets for 2021 were $131.795B, a 3.14% increase from 2020.
  • Novartis AG total assets for 2020 were $127.778B, a 7.95% increase from 2019.
  • Novartis AG total assets for 2019 were $118.37B, a 18.68% decline from 2018.
Novartis AG Annual Total Assets
(Millions of US $)
2021 $131,795
2020 $127,778
2019 $118,370
2018 $145,563
2017 $133,079
2016 $130,124
2015 $131,556
2014 $125,387
2013 $126,254
2012 $124,191
2011 $117,496
2010 $123,318
2009 $95,505
Novartis AG Quarterly Total Assets
(Millions of US $)
2022-03-31 $125,218
2021-12-31 $131,795
2021-09-30 $121,209
2021-06-30 $124,015
2021-03-31 $121,752
2020-12-31 $127,778
2020-09-30 $129,678
2020-06-30 $123,763
2020-03-31 $123,097
2019-12-31 $118,370
2019-09-30 $115,971
2019-06-30 $116,294
2019-03-31 $137,946
2018-12-31 $145,563
2018-09-30 $142,994
2018-06-30 $142,058
2018-03-31 $135,524
2017-12-31 $133,079
2017-09-30 $134,972
2017-06-30 $133,749
2017-03-31 $131,986
2016-12-31 $0
2016-09-30 $134,007
2016-06-30 $131,436
2016-03-31 $132,448
2015-12-31 $131,556
2015-09-30 $132,927
2015-06-30 $135,413
2015-03-31 $134,935
2014-12-31 $125,387
2014-09-30 $125,377
2014-06-30 $125,768
2014-03-31 $125,332
2013-12-31 $126,254
2013-09-30 $124,594
2013-06-30 $121,072
2013-03-31 $121,011
2012-12-31 $124,191
2012-09-30 $121,219
2012-06-30 $118,492
2012-03-31 $119,411
2011-12-31 $117,496
2011-09-30 $121,377
2011-06-30 $125,915
2011-03-31 $127,218
2010-12-31 $123,318
2010-09-30 $124,628
2010-06-30 $96,924
2010-03-31 $95,795
2009-12-31 $95,505
2009-09-30 $90,686
2009-06-30 $84,274
2009-03-31 $77,970
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $181.123B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $472.758B 18.18
Eli Lilly (LLY) United States $297.134B 35.06
Pfizer (PFE) United States $281.050B 9.80
AbbVie (ABBV) United States $264.095B 11.58
Merck (MRK) United States $232.650B 13.14
GlaxoSmithKline (GSK) United Kingdom $108.662B 12.69
Novo Nordisk (NVO) Denmark $0.000B 32.27